Navigation Links
Lixte Biotechnology Holdings Announces That Novel Compounds Being Developed as Potential Treatments for Brain Tumors Have Positive Activity in a Mouse Model of Human Pancreatic Cancer
Date:8/8/2008

EAST SETAUKET, N.Y., Aug. 8 /PRNewswire-FirstCall/ -- Lixte Biotechnology Holdings, Inc. (OTC Bulletin Board: LIXT) announced today that lead compounds from each of two different types of drugs being developed as potential treatment for specific types of brain cancers have activity against human pancreatic cancers in a mouse model.

Dr. John S. Kovach, President and CEO of Lixte, said, "Lixte previously reported that lead compounds from each of two different classes of pharmacologic agents have significant inhibitory activity against several types of human cancers in the test tube and against brain cancers in animal models. We have now found that two different lead compounds also have statistically significant activity against human pancreatic cancer cells growing in mice. These are early studies and there is no evidence that these drugs are able to eliminate pancreatic cancers but rather slow their growth. We are encouraged, however, that two classes of our drugs have activity against this devastating cancer in addition to glioblastoma multiforme, the most common and most malignant form of brain cancer."

About Lixte Biotechnology Holdings, Inc.:

Lixte Biotechnology Holdings, Inc. is a cancer therapeutics and diagnostics company. Founded as a biomarker-diagnostics company in 2005, Lixte develops new chemotherapy drugs targeting molecular abnormalities of common human cancers.

Forward-Looking Statements:

This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future product demand, supply, manufacturing, costs, marketing and pricing factors are all forward-looking statements. These statements are generally accompanied by words
'/>"/>

SOURCE Lixte Biotechnology Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Lixte Biotechnology Holdings Announces That Anti-Cancer Activity Against Glioblastoma in an Animal Model Was Reported at the Annual Meeting of the American Association of Cancer Research
2. Lixte Biotechnology Holdings, Inc. Announces Completion of Private Placement
3. Generex Biotechnology Corporation Initiation Coverage Review Issued By Scimitar Equity, LLC
4. Dr. Ari Kiev to be Featured Speaker at Biotechnology Conference Wall Street Unplugged: The Trout Group Investor Seminar in New York July 30
5. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells
6. Champions Biotechnology Begins Preclinical Development of Its Lead Oncology Drug Candidate
7. Genetic Engineering & Biotechnology News Reports on the Growing Role of Ion-Channel Studies in Global Biotech R&D
8. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
9. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
10. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
11. Innocoll Announces Dosing of Last Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-Operative Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... CHENGDU, China , Jan. 23, 2015 Tianyin ... pharmaceutical company that specializes in the development and sale ... branded generics and active pharmaceutical ingredients (API) today announced ... Facility (JCM) API operation. 1. Following the ...
(Date:1/22/2015)... 22, 2015  ResMed Inc. (NYSE: RMD ) today ... for the quarter was $423.0 million, a 10 percent increase ... percent increase on a constant currency basis). Net income was ... quarter ended December 31, 2013. Diluted earnings per share for ...
(Date:1/22/2015)... , Jan. 22, 2015  Profil Institute for Clinical ... diabetes and obesity, announced today a new textbook,  Translational ... published by Springer, a leading global scientific publisher. ... and illustrate techniques for use in early phase clinical ...
Breaking Medicine Technology:TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 2New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 3
... MiMedx Group, Inc. (OTC Bulletin Board: MDXG ... protected biomaterial-based products, announced today that it has received ... product using the Company,s proprietary HydroFix™ technology. ... is in addition to the Company,s previous certification for ...
... Dey Pharma, L.P. today announced that it has signed ... pharma company headquartered in Sweden, for the exclusive marketing ... EpiPen Auto-Injector is used for emergency treatment of severe ... a couple of minutes, and may be life-threatening. ...
Cached Medicine Technology:MiMedx Receives Additional CE Certification for Its HydroFix™ Technology 2MiMedx Receives Additional CE Certification for Its HydroFix™ Technology 3MiMedx Receives Additional CE Certification for Its HydroFix™ Technology 4Mylan's Dey Pharma Partners with Meda to Market EpiPen® Auto-Injector in Europe 2Mylan's Dey Pharma Partners with Meda to Market EpiPen® Auto-Injector in Europe 3
(Date:1/22/2015)... January 23, 2015 VogueQueen is a seasoned ... prices and many designers are thrilled to have it lead ... announces its new collection of prom dresses for the global ... drive the strategic vision and he focuses on continuing the ...
(Date:1/22/2015)... Angelweddingdress is a famous wedding dress company offering many trendy ... on Facebook, Twitter, and Pinterest. The fans will have an ... lottery every week. , Moreover, the company has extended its ... Angelweddingdress homepage for more information. , Angelweddingdress is ...
(Date:1/22/2015)... 2015 AngelWeddingDress, the premier women’s dress ... wedding dresses. View website of AngelWeddingDress.com to ... maternity wedding dresses online for a bridal party. AngelWeddingDress ... quality for them. Its maternity wedding dresses are specially ...
(Date:1/22/2015)... Juvent Sports ( http://www.juventsports.com ) and ... Merchandise Show to bestow a Juvent Sports Achievement award ... Arlene McKitrick. The award commemorated and congratulated McKitrick for ... She won her first amateur tournament in 1979 and ...
(Date:1/22/2015)... Thousand of GranuFlo lawsuits ( http://www.granuflolawsuit2014.com/ ... GranuFlo and NaturaLyte dialysis concentrates continue to move forward ... Court, District of Massachusetts, Bernstein Liebhard LLP reports. According ... remanded a case filed by the state of Louisiana ...
Breaking Medicine News(10 mins):Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4
... -- Heart palpitations and high blood pressure are strong ... atrial fibrillation, a new study reports. Atrial fibrillation ... death. It was already known that high blood pressure ... to the researchers, this is the first study to ...
... Breast cancer stem cells wear a cell surface protein that ... potent tumor-generating cells and flagging their vulnerability to a drug, ... report online in Journal of Clinical Investigation . ... cells and also found that it,s targetable with a small ...
... May 15 (HealthDay News) -- Researchers have identified gene ... they say their findings could help identify patients who ... from the University of California-Los Angeles, say their findings ... Parkinson,s disease is a progressive movement disorder marked by ...
... May 15 (HealthDay News) -- The lives of more than ... and 2008 by the U.S. President,s Emergency Plan for AIDS ... risk of death from all causes by 16 percent to ... Medicine researchers found. The researchers said this is the first ...
... , TUESDAY, May 15 (HealthDay News) -- The blockbuster ... heart patients, will go off patent in the United ... Adherence rates will improve as a result, and ... Dr. Gregg Fonarow, a professor of medicine and director ...
... Older, sicker, high-risk patients who undergo one of the ... in larger, busier hospitals, according to new research by ... research showed the experience level of the surgeon doing ... The results, based on data gathered throughout the ...
Cached Medicine News:Health News:Palpitations May Signal Future Heart Rhythm Problem 2Health News:Scientists discover marker to identify, attack breast cancer stem cells 2Health News:Scientists discover marker to identify, attack breast cancer stem cells 3Health News:Scientists discover marker to identify, attack breast cancer stem cells 4Health News:Genes Might Be Key to Parkinson's Spread 2Health News:Plavix's New Generic Status Could Be Boon for Patients 2Health News:Higher hospital volume more important than surgeon experience in outcome of prostate cancer surgery 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: